Authors
Valeria Epifani, Paola Anselmo, Fabio Arcidiacono, Giulia Mascari, Simonetta Saldi, Isabella Palumbo, Michelina Casale, Gianluca Ingrosso, Vittorio Bini, Fabio Trippa, Cynthia Aristei
Published in
Brachytherapy. Sep 26, 2026. Epub Sep 26, 2026.
Abstract
To assess late toxicities, cosmesis, and oncological outcomes in patients treated with Partial Breast Irradiation (PBI) using interstitial multi-catheter high dose-rate brachytherapy.
From 2003 to 2023, 292 patients were enrolled in a prospective observational study (follow-up up to 20 years).
age ≥40 years; ECOG 0-2; ductal carcinoma in situ; invasive non lobular carcinoma; tumor size ≤2.5 cm; negative axillary lymph nodes; surgical margins ≥2 mm. PBI dose was 32 Gy in 8 fractions over 4 days.
Invasive carcinoma accounted for 92.1% of cases. Late toxicities (mainly telangiectasia, fibrosis, liponecrosis) occurred in 100/286 patients evaluated (35%). Cosmetic outcomes were rated as excellent/good in 96% of cases. Ipsilateral breast tumor recurrence occurred in 10 patients (3.4%) with a 5-year cumulative incidence of 1.8% and 3.8% at 10 and 15 years. Breast cancer-free specific survival was 98.4% after 5 years, 95.7% after 10 years, and 94% after 15 years. Overall survival was 93% after 5 years, 69% after 10 years, and 53.4% after 15 years.
PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.
PMID:
42800727
Bibliographic data and abstract were imported from PubMed on 27 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0